Pharmaceuticals

Harrow

Harrow released FY2026 Q1 earnings on May 11 After-Market EST, actual revenue USD 44.2 M (forecast USD 52.49 M), actual EPS USD -0.7413 (forecast USD -0.4014)

Harrow FY2026 Q1 Earnings Release on May 11 After-Market EST, Forecast Revenue USD 52.49 M, EPS USD -0.4014

Harrow released FY2025 Annual Earnings on March 2 After-Market EST, actual revenue USD 272.3 M (forecast USD 271.64 M), actual EPS USD -0.1397 (forecast USD 0.06)

Harrow released FY2025 Q4 earnings on March 2 After-Market (EST), actual revenue USD 89.09 M (forecast USD 88.42 M), actual EPS USD 0.17 (forecast USD 0.3662)

Harrow to Release FY2025 Q4 Earnings on March 2 After-Market EST, Forecast Revenue USD 88.42 M, EPS USD 0.3662

Harrow Inc CFO Discloses Stock Ownership Changes

Harrow Inc. Chairman Exercises Options and Sells Shares

William Blair Maintains Buy Rating on HROW: Strong Product Performance and Effective Cost Management

Harrow released FY2025 Q3 earnings on November 10 After-Market EST, actual revenue USD 71.64 M (forecast USD 73.7 M), actual EPS USD 0.03 (forecast USD 0.2614)

Harrow released FY2025 9 Months earnings on November 10 After-Market EST, actual revenue USD 183.21 M, actual EPS USD -0.3388

Harrow to Release FY2025 Q3 Earnings on November 10 After-Market EST, Forecast Revenue USD 73.7 M, EPS USD 0.2614

Analyst Knickerbocker Gives Harrow Health Strong Buy Rating

Analyst Reiterates Hold Rating on Harrow Health Stock

O’Neil and B. Riley Maintain a Buy Rating for Harrow Health Stock and Set Target Prices

Harrow Inc. amends 8-K report to include merger agreement with Melt Pharmaceuticals, Inc.

Analyst Knickerbocker Reiterates Strong Buy Rating on Harrow Health Stock

Harrow Inc. Reaches $40 Million Credit Facility Agreement with Fifth Third Bank

HARROW Acquires MELT PHARMACEUTICALS

Harrow Health Receives Buy Rating After Strategic Debt Restructuring and Acquisition of MELT

Craig Hallum Raises Harrow, Inc. Target Price to $64.00

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

HROW

HROWL

HROWM

Harrow Inc. announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for treating vernal keratoconjunctivitis in children. This steroid-sparing therapy aims to reduce corticosteroid dependence and associated risks like glaucoma. CEO Mark Baum highlighted this as a key step in Harrow's ophthalmology strategy, with William Blair noting it serves as supplemental revenue while strengthening the company's portfolio.

benzinga_article

Harrow Health Pref Share HROWL 8.625 04/30/26

Harrow Health Pref Share HROWM 11.875 12/31/27

Jazz Pharma

Clover Health Investments

Harrow Adds Another Piece To Ophthalmology Strategy

GEHC

OPCH

Recent insider buying by CEOs and CFOs at several companies signals confidence in future stock performance. Notable examples include FTI Consulting, Option Care Health, Harrow Health, GE HealthCare Technologies, and AECOM, where both executives purchased shares, indicating they believe the stocks are undervalued. This trend suggests that management sees potential for growth despite current market pessimism, making these situations worth monitoring for investors.

GE HealthCare Tech

Option Care Health

Aecom

FTI Consulting

Alpha Buying: When CEOs and CFOs Buy Together

ARKG

LABU

SBIO

Harrow, Inc. reported a Q1 2026 revenue of $44.2 million, down from $47.83 million, with a net loss widening to $27.6 million. Despite this, the company reaffirmed its full-year revenue guidance of $350 million to $365 million, indicating confidence in its product portfolio. Analysts remain cautious about the impact of rising losses and product concentration on future revenue growth.

Simplywall

VanEck Biotech ETF

VG Health

iShares Biotechnology ETF

Health Care Select Sector SPDR

iShares Global Healthcare

SPDR Pharmac

SPDR S&P Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares US Pharma

Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 Losses - What's Changed

Harrow (HROW) reported a Q1 loss of US$27.6 million, raising concerns about its profitability. Revenue fell to US$44.2 million from US$89.1 million in Q4 2025, with a trailing twelve-month revenue of US$268.7 million. Despite forecasts of 50.63% earnings growth, the company's history of increasing losses challenges bullish narratives. The current share price of US$29.03 is significantly below its DCF fair value of US$328.90, leading to skepticism about future profitability. Analysts predict 26.8% revenue growth, but recent quarterly fluctuations highlight execution risks.

Harrow (HROW) Q1 Loss Of US$27.6 Million Rekindles Profitability Concerns

PSIX

DXYZ

CAMT

FLNC

NVTS

INBX

HIMS

Power Solutions(PSIX) fell 39.15%, with a trading turnover 202.8 Million USD, and a year-to-date fell 33.5%. ZoomInfo Tech(GTM) fell 32.78%, with a trading turnover 172.5 Million USD, and a year-to-date fell 60.1%. Destiny Tech100(DXYZ) fell 25.04%, with a trading turnover 678.1 Million USD, and a year-to-date rose 74.3%.

Top Gainers&Losers

Power Solutions

ZoomInfo Tech

Destiny Tech100

Under Armour

Camtek

Fluence Energy

Navitas Semiconductor

Inhibrx Biosciences

Hims & Hers Health

Top 10 US Stock Losers (5.12)

Harrow Inc (NASDAQ:HROW) reported Q1 2026 revenues of $44.2 million, with an adjusted EBITDA of -$12.7 million, impacted by an $8 million gross-to-net issue with its product Vivi. The company has expanded its sales force to drive growth and reaffirmed its full-year revenue guidance of $350 million to $365 million, anticipating strong performance in the second half due to new product launches and improved pricing strategies. Demand for core products remains strong, indicating sustainable market share capture and potential for profitable revenue growth.

Transcript: Harrow Q1 2026 Earnings Conference Call

Earnings Watch

Harrow | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 44.2 M

Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.

Harrow(HROW.US)